Prices of 851 essential drug formulations cut in past 2 year: Government Ruby Khatun Khatun15 March 2018 10:00 AM ISTNew Delhi: Prices of 851 essential drug formulations were cut, mostly in the 5-40 percent range, in the past 2 years, the government said.In a written...
Roche CEO says new drugs will offset biosimilar incursions Ruby Khatun Khatun15 March 2018 9:45 AM ISTZURICH: Swiss drugmaker Roche will be able to compensate or overcompensate for falling revenue from patent-expired drugs facing competition from...
Teva rebuffs EU pay-for-delay charge at hearing Ruby Khatun Khatun15 March 2018 9:30 AM ISTBRUSSELS: Israeli drugmaker Teva rebuffed EU antitrust charges of making an illegal deal with rival Cephalon to delay selling a cheaper generic...
Zydus Cadila gets USFDA nod for Tizanidine tablets Ruby Khatun Khatun14 March 2018 10:30 AM ISTNew Delhi: Cadila Healthcare said its group firm Zydus Cadila has received final approval from the US health regulator for its generic version of...
Cognizant to acquire bolder healthcare solutions Ruby Khatun Khatun14 March 2018 10:00 AM ISTCognizant announced it has agreed to acquire Bolder Healthcare Solutions, a privately-held provider of revenue cycle management (RCM) solutions to...
GSK wins new reprieve as Hikma's generic Advair delayed again Ruby Khatun Khatun14 March 2018 9:45 AM ISTGlaxoSmithKline (GSK) has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a...
Impax broke US antitrust law by delaying generic drug, jury told Ruby Khatun Khatun14 March 2018 9:30 AM ISTBOSTON: Impax Laboratories Inc went to trial on Monday over allegations by major retailers and consumers that the company agreed to delay launching a...
Health bodies push for compulsory licence for two drugs on MDR-TB Ruby Khatun Khatun13 March 2018 10:30 AM ISTNew Delhi: Survivors of drug-resistant tuberculosis, health organizations and the TB community have appealed to Prime Minister Narendra Modi to allow...
AstraZeneca sees pivotal lung cancer trial results later in 2018 Ruby Khatun Khatun13 March 2018 10:00 AM ISTLONDON: AstraZeneca now expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018,...
Biogen to buy Pfizer's neurology drug in deal nearing 600 million dollars Ruby Khatun Khatun13 March 2018 9:45 AM ISTBiogen Inc said on Monday it would buy Pfizer Inc’s experimental treatment for a symptom associated with schizophrenia in a deal that could near $600...
Reckitt CEO stands by Mead Johnson deal, despite Pfizer option Ruby Khatun Khatun13 March 2018 9:30 AM ISTLONDON: Reckitt Benckiser has no regrets about its $17 billion acquisition of Mead Johnson last year, its chief executive said, even though there are...
Neuberg Diagnostics to invest Rs 300 crore for expansion Ruby Khatun Khatun12 March 2018 10:30 AM ISTMumbai: Neuberg Diagnostics, an alliance of five leading pathology laboratories from India, South Africa and the UAE, is planning to invest Rs 300...
